Glucocorticoids and cardiovascular risk factors

Endocrinology and Metabolism Clinics of North America

Volumn 40, Issue 2, 2011, Pages 409-417

  Strohmayer, Erika A ^a   Krakoff, Lawrence R ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

C reactive protein; Cardiovascular risk; Diabetes; Dyslipidemia; Glucocorticoids; Glucose metabolism; Hypertension

Indexed keywords

CHOLESTEROL; DEXAMETHASONE; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN; HYDROCORTISONE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN; MEPREDNISONE; PREDNISOLONE; PREDNISONE; TRIACYLGLYCEROL;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; ENZYME METABOLISM; GLUCOSE METABOLISM; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPID METABOLISM; LIPOLYSIS; LONG TERM CARE; NEUROLOGIC DISEASE; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SARCOIDOSIS; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TEMPORAL ARTERITIS; UVEITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DYSLIPIDEMIAS; GLUCOCORTICOIDS; HUMANS; INSULIN RESISTANCE; LIPIDS; PREVALENCE; RISK FACTORS;

EID: 79955723009     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2011.01.011     Document Type: Review

References (65)

1. Plotz C.M., Knowlton A.I., Ragan C. The natural history of Cushing's syndrome. Am J Med 1952, 13(5):597-614.
2. Clore J.N., Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009, 15(5):469-474.
3. Chan H.W., Cheung C.Y., Liu Y.L., et al. Prevalence of abnormal glucose metabolism in Chinese renal transplant recipients: a single centre study. Nephrol Dial Transplant 2008, 23(10):3337-3342.
4. Bonato V., Barni R., Cataldo D., et al. Analysis of posttransplant diabetes mellitus prevalence in a population of kidney transplant recipients. Transplant Proc 2008, 40(6):1888-1890.
5. Iwamoto T., Kagawa Y., Naito Y., et al. Steroid-induced diabetes mellitus and related risk factors in patients with neurologic diseases. Pharmacotherapy 2004, 24(4):508-514.
6. Panthakalam S., Bhatnagar D., Klimink P. The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. Scott Med J 2004, 49(4):139-141.
7. Pagano G., Cavalloperin P., Cassader M., et al. An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. J Clin Invest 1983, 72(5):1814-1820.
8. Rizza R.A., Mandarino L.J., Gerich J.E. Cortisol-induced insulin resistance in man: impaired suppression of glucose-production and stimulation of glucose-utilization due to a postreceptor defect of insulin action. J Clin Endocrinol Metab 1982, 54(1):131-138.
9. Abdelmannan D., Tahboub R., Genuth S., et al. Effect of dexamethasone on oral glucose tolerance in normal individuals. Endocr Pract 2010, 16(5):770-777.
10. Nicod N., Giusti V., Besse C., et al. Metabolic adaptations to dexamethasone-induced insulin resistance in healthy volunteers. Obes Res 2003, 11(5):625-631.
11. Weinstein S.P., Wilson C.M., Pritsker A., et al. Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. Metabolism 1998, 47(1):3-6.
12. Ruzzin J., Wagman A.S., Jensen J. Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor. Diabetologia 2005, 48(10):2119-2130.
13. Buren J., Lai Y.C., Lundgren M., et al. Insulin action and signalling in fat and muscle from dexamethasone-treated rats. Arch Biochem Biophys 2008, 474(1):91-101.
14. Henriksen J.E., Alford F., Vaag A., et al. Intracellular skeletal muscle glucose metabolism is differentially altered by dexamethasone treatment of normoglycemic relatives of type 2 diabetic patients. Metabolism 1999, 48(9):1128-1135.
15. Ekstrand A., Schalin Jantti C., Lofman M., et al. The effect of (steroid) immunosuppression on skeletal muscle glycogen metabolism in patients after kidney transplantation. Transplantation 1996, 61(6):889-893.
16. van Raalte D.H., Ouwens D.M., Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?. Eur J Clin Invest 2009, 39(2):81-93.
17. Jin J.Y., DuBois D.C., Almon R.R., et al. Receptor/gene-mediated pharmacodynamic effects of methylprednisolone on phosphoenolpyruvate carboxykinase regulation in rat liver. J Pharmacol Exp Ther 2004, 309(1):328-339.
18. Dirlewanger M., Schneiter P., Paquot N., et al. Effects of glucocorticoids on hepatic sensitivity to insulin and glucagon in man. Clin Nutr 2000, 19(1):29-34.
19. Stumvoll M., Goldstein B.J., van Haeften T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005, 365(9467):1333-1346.
20. Vila G., Krebs M., Riedl M., et al. Acute effects of hydrocortisone on the metabolic response to a glucose load: increase in first-phase insulin secretion. Eur J Endocrinol 2010, 163(2):225-231.
21. Kalhan S.C., Adam P.A. Inhibitory effect of prednisone on insulin-secretion in man: model for duplication of blood-glucose concentration. J Clin Endocrinol Metab 1975, 41(3):600-610.
22. Besse C., Nicod N., Tappy L. Changes in insulin secretion and glucose metabolism induced by dexamethasone in lean and obese females. Obes Res 2005, 13(2):306-311.
23. Matsumoto K., Yamasaki H., Akazawa S., et al. High-dose but not low-dose dexamethasone impairs glucose tolerance by inducing compensatory failure of pancreatic beta-cells in normal men. J Clin Endocrinol Metab 1996, 81:2621-2626.
24. Beard J.C., Halter J.B., Best J.D., et al. Dexamethasone-induced insulin resistance enhances b-cell responsiveness to glucose level in normal men. Am J Physiol 1984, 247(5):E592-E596.
25. Dessein P.H., Joffe B.I. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 2006, 54(9):2765-2775.
26. Gremlich S., Roduit R., Thorens B. Dexamethasone induces posttranslational degradation of GLUT2 and inhibition of insulin secretion in isolated pancreatic beta cells. Comparison with the effects of fatty acids. J Biol Chem 1997, 272(6):3216-3222.
27. Khan A., Ostenson C.G., Berggren P.O., et al. Glucocorticoid increases glucose cycling and inhibits insulin release in pancreatic-islets of ob/ob mice. Am J Physiol 1992, 263(4):E663-E666.
28. Ullrich S., Berchtold S., Ranta F., et al. Serum- and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion. Diabetes 2005, 54(4):1090-1099.
29. Ranta F., Avram D., Berchtold S., et al. Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4. Diabetes 2006, 55(5):1380-1390.
30. Miller L.W. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002, 2(9):807-818.
31. Zimmerman J., Fainaru M., Eisenberg S. The effects of prednisone therapy on plasma lipoproteins and apolipoproteins: a prospective study. Metabolism 1984, 33(6):521-526.
32. Ettinger W.H., Goldberg A.P., Applebaum-Bowden D., et al. Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 1987, 83(3):503-508.
33. el-Shaboury A.H., Hayes T.M. Hyperlipidaemia in asthmatic patients receiving long-term steroid therapy. Br Med J 1973, 2(5858):85-86.
34. Keogh A., Macdonald P., Harvison A., et al. Initial steroid-free versus steroid-based maintenance therapy and steroid withdrawal after heart transplantation: two views of the steroid question. J Heart Lung Transplant 1992, 11(2 Pt 2):421-427.
35. Curtis J.J., Galla J.H., Woodford S.Y., et al. Effect of alternate-day prednisone on plasma lipids in renal transplant recipients. Kidney Int 1982, 22(1):42-47.
36. Brotman D.J., Girod J.P., Garcia M.J., et al. Effects of short-term glucocorticoids on cardiovascular biomarkers. J Clin Endocrinol Metab 2005, 90(6):3202-3208.
37. Taskinen M.R., Kuusi T., Yki-Jarvinen H., et al. Short-term effects of prednisone on serum lipids and high density lipoprotein subfractions in normolipidemic healthy men. J Clin Endocrinol Metab 1988, 67(2):291-299.
38. Ettinger W.H., Hazzard W.R. Elevated apolipoprotein-B levels in corticosteroid-treated patients with systemic lupus erythematosus. J Clin Endocrinol Metab 1988, 67(3):425-428.
39. Sholter D.E., Armstrong P.W. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 2000, 16(4):505-511.
40. Esteve E., Ricart W., Fernandez-Real J.M. Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr 2005, 24(1):16-31.
41. Garcia-Gomez C., Nolla J.M., Valverde J., et al. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy. Eur J Clin Invest 2008, 38(9):686-692.
42. Stern M.P., Kolterman O.G., Fries J.F., et al. Adrenocortical steroid treatment of rheumatic diseases. Effects on lipid metabolism. Arch Intern Med 1973, 132(1):97-101.
43. Henze K., Chait A., Albers J.J., et al. Hydrocortisone decreases the internalization of low density lipoprotein in cultured human fibroblasts and arterial smooth muscle cells. Eur J Clin Invest 1983, 13(2):171-177.
44. Hirsch L.J., Mazzone T. Dexamethasone modulates lipoprotein metabolism in cultured human monocyte-derived macrophages. Stimulation of scavenger receptor activity. J Clin Invest 1986, 77(2):485-490.
45. Bagdade J.D., Yee E., Albers J., et al. Glucocorticoids and triglyceride transport: effects on triglyceride secretion rates, lipoprotein lipase, and plasma lipoproteins in the rat. Metabolism 1976, 25(5):533-542.
46. Boden G., Shulman G.I. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002, 32(Suppl 3):14-23.
47. Cole T.G., Wilcox H.G., Heimberg M. Effects of adrenalectomy and dexamethasone on hepatic lipid metabolism. J Lipid Res 1982, 23(1):81-91.
48. Lemke U., Krones-Herzig A., Berriel Diaz M., et al. The glucocorticoid receptor controls hepatic dyslipidemia through Hes1. Cell Metab 2008, 8(3):212-223.
49. Rockall A.G., Sohaib S.A., Evans D., et al. Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography. Eur J Endocrinol 2003, 149(6):543-548.
50. Dourakis S.P., Sevastianos V.A., Kaliopi P. Acute severe steatohepatitis related to prednisolone therapy. Am J Gastroenterol 2002, 97(4):1074-1075.
51. Itoh S., Igarashi M., Tsukada Y., et al. Nonalcoholic fatty liver with alcoholic hyalin after long-term glucocorticoid therapy. Acta Hepatogastroenterol (Stuttg) 1977, 24(6):415-418.
52. Kitahara A., Saga K., Koide S., et al. Iatrogenic hyperadrenocorticism and steatohepatitis caused by unapproved medicine. Intern Med 2008, 47(13):1231-1236.
53. Nanki T., Koike R., Miyasaka N. Subacute severe steatohepatitis during prednisolone therapy for systemic lupus erythematosis. Am J Gastroenterol 1999, 94(11):3379.
54. Macfarlane D.P., Forbes S., Walker B.R. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol 2008, 197(2):189-204.
55. Rockall A.G., Sohaib S.A., Evans D., et al. Computed tomography assessment of fat distribution in male and female patients with Cushing's syndrome. Eur J Endocrinol 2003, 149(6):561-567.
56. Rebuffe-Scrive M., Krotkiewski M., Elfverson J., et al. Muscle and adipose tissue morphology and metabolism in Cushing's syndrome. J Clin Endocrinol Metab 1988, 67(6):1122-1128.
57. Nordborg E., Schaufelberger C., Bosaeus I. The effect of glucocorticoids on fat and lean tissue masses in giant cell arteritis. Scand J Rheumatol 1998, 27(2):106-111.
58. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24(4):683-689.
59. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342(3):145-153.
60. Krakoff L.R., Elijovich F. Cushing's syndrome and exogenous glucocorticoid hypertension. Clin Endocrinol Metab 1981, 10(3):479-488.
61. Ridker P.M., Morrow D.A. C-reactive protein, inflammation, and coronary risk. Cardiol Clin 2003, 21(3):315-325.
62. Andersson R., Malmvall B.E., Bengtsson B.A. Acute phase reactants in the initial phase of giant cell arteritis. Acta Med Scand 1986, 220(4):365-367.
63. Mallya R.K., Hind C.R., Berry H., et al. Serum C-reactive protein in polymyalgia rheumatica. A prospective serial study. Arthritis Rheum 1985, 28(4):383-387.
64. Renvert S., Lindahl C., Roos-Jansaker A.M., et al. Short-term effects of an anti-inflammatory treatment on clinical parameters and serum levels of C-reactive protein and proinflammatory cytokines in subjects with periodontitis. J Periodontol 2009, 80(6):892-900.
65. Dernellis J., Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004, 25(13):1100-1107.